CD8+ T cells in HIV control, cure and prevention
HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy
Chronic viral infections can appear in two very different forms: those that are typically
immunologically contained after acute symptomatic infection, such as Epstein-Barr virus …
immunologically contained after acute symptomatic infection, such as Epstein-Barr virus …
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy
Background. Spontaneous control of human immunodeficiency virus (HIV) infection has
been documented in a minority of HIV-infected individuals. The mechanisms behind this …
been documented in a minority of HIV-infected individuals. The mechanisms behind this …
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation
TJ Henrich, Z Hu, JZ Li, G Sciaranghella… - The Journal of …, 2013 - academic.oup.com
Background. The long-term impact of allogeneic hematopoietic stem cell transplantation
(HSCT) on human immunodeficiency virus type 1 (HIV-1) reservoirs in patients receiving …
(HSCT) on human immunodeficiency virus type 1 (HIV-1) reservoirs in patients receiving …
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers
O Lambotte, G Ferrari, C Moog, NL Yates, HX Liao… - Aids, 2009 - journals.lww.com
Objective: To determine the spectrum of antiviral antibodies in HIV-1-infected individuals in
whom viral replication is spontaneously undetectable, termed HIV controllers (HICs) …
whom viral replication is spontaneously undetectable, termed HIV controllers (HICs) …
Unravelling the mechanisms of durable control of HIV-1
Untreated HIV-1 infection typically progresses to AIDS within 10 years, but less than 1% of
infected individuals remain healthy and have normal CD4+ T cell counts and undetectable …
infected individuals remain healthy and have normal CD4+ T cell counts and undetectable …
Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in …
JR Bailey, AR Sedaghat, T Kieffer, T Brennan… - Journal of …, 2006 - Am Soc Microbiol
Antiretroviral therapy can reduce human immunodeficiency virus type 1 (HIV-1) viremia to
below the detection limit of ultrasensitive clinical assays (50 copies of HIV-1 RNA/ml) …
below the detection limit of ultrasensitive clinical assays (50 copies of HIV-1 RNA/ml) …
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
NA Doria-Rose, RM Klein, MG Daniels, S O'Dell… - Journal of …, 2010 - Am Soc Microbiol
Induction of antibodies that neutralize a broad range of human immunodeficiency virus type
1 (HIV-1) isolates is a major goal of vaccine development. To study natural examples of …
1 (HIV-1) isolates is a major goal of vaccine development. To study natural examples of …
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
Some HIV-1–infected patients develop broad and potent HIV-1 neutralizing antibodies
(bNAbs) that when passively transferred to mice or macaques can treat or prevent infection …
(bNAbs) that when passively transferred to mice or macaques can treat or prevent infection …
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
NA Doria-Rose, RM Klein, MM Manion, S O'Dell… - Journal of …, 2009 - Am Soc Microbiol
Induction of broadly cross-reactive neutralizing antibodies (NAb) is an important goal for a
prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine. Some HIV-infected …
prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine. Some HIV-infected …